# Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Source: https://onco.cc/trials/nct04586478/  
OnCo record `nct04586478` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of single dose of CNCT19 in non-Hodgkin lymphoma, run by Juventas Cell Therapy Ltd., now recruiting.

## Summary

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma is a phase 2 interventional study registered as NCT04586478 by Juventas Cell Therapy Ltd., with 60 participants planned, started 2020-10-26 and due to reach its primary completion in 2024-03-30. Interventions recorded: single dose of CNCT19.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04586478
- Phase: 2
- Setting: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
- Sponsor: Juventas Cell Therapy Ltd.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT04586478: https://clinicaltrials.gov/study/NCT04586478

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct04586478.json